Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on July 14, 2011. The filing discloses a material event regarding the company's intellectual property portfolio under Item 7.01 Regulation FD Disclosure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure regarding patent allowances and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the receipt of a notice of allowance from the United States Patent and Trademark Office for two specific applications:
- U.S. Patent Application 12/939,897
- U.S. Patent Application 12/939,914
Both applications are entitled "Compositions to Effect Neuronal Growth."
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.01) but does not contain specific forward-looking guidance, financial outlook, or management commentary beyond the announcement of the patent allowance. The document includes standard legal disclaimers stating that the information is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.01) for details on the commercial implications of the patent allowance.
- Confirm the specific claims and scope of U.S. Patent Applications 12/939,897 and 12/939,914.
- Review subsequent filings to determine if these patents were officially issued and if they impact the company's product pipeline.
- Note the discrepancy between the requested company name (Palisade Bio, Inc.) and the actual registrant (Neuralstem, Inc.).